ClinPGx Blog (Page 43)

Sign in Subscribe

More issues

Updated UGT1A1 VIP Summary

We have updated the UGT1A1 VIP summary to provide more in-depth information on this important pharmacogene. UGT1A1 is a member of the uridine diphosphate glucuronosyltransferase (UGT) enzyme family, and is responsible for the glucuronidation of target substrates. The transfer of glucuronic acid renders xenobiotics and other endogenous compounds water

The PGRN Translational Pharmacogenetics Program (TPP) publishes paper on overcoming challenges of real-world implementation

The Translational Pharmacogenetics Program (TPP) is a Pharmacogenomics Research Network (PGRN)-led initiative with the goal to identify barriers and develop real-world solutions to implement evidence-based pharmacogenetic tests in diverse health care settings. The participating sites include 6 implementation institutions (Universityof Maryland, University of Florida, St. Jude Children&

Implementing pharmacogenetics: more than one gene at a time

It has been well recognized that drug response is complex and determined by not only one gene, but rather by the interplay of multiple gene products. However, studies of combined impact of more than one gene are scarce, limiting the potential for making strong dosing recommendations based on multiple genes.

Clinical notes used for pharmacovigilance

A team at Stanford University have computationally extracted information from free-text clinical notes in medical records, in order to identify drug-induced adverse events and adverse reactions from drug-drug interactions. Information from the notes was deidentified and transformed into a patient-feature matrix using a medical ontology hierarchy

Venlafaxine Pathway

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders. The molecular targets of venlafaxine are the serotonin and norepinephrine transporters, resulting in inhibition of serotonin and noradrenaline reuptake from the synaptic cleft. A new pathway is posted on PharmGKB summarizing the metabolism of venlafaxine.

Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics

We updated the Mycophenolic acid Pathway in collaboration with Kinjal Sanghavi and Dr. Vishal Lamba from the University of Minnesota.Mycophenolic Acid (MPA) is an immunosuppressive agent and is indicated as prophylactic agent in patients receiving allogeneic renal, cardiac or hepatic transplants. This PharmGKB pathway describes the steps and metabolites

GWAS in PGx: Pharmacogenomics Special Issue

This month's Future Medicine Pharmacogenomics Journal focuses on genome-wide association studies (GWAS) in PGx. Articles include highlights from the latest PGx GWAS, and topics covering data analysis techniques, rare variants, and direct-to-consumer PGx testing. Pharmacogenomics, March 2013, Volume 14, Number 4 Special Focus Issue: Genome-

Spanish Association of Hospital Pharmacists: Excellence Course in PGx

The current issue of the European Journal of Hospital Pharmacy has a report from our collaborators at Leiden University Medical Center regarding the Excellence Course in PGx organized by the Spanish Association of Hospital Pharmacists. The course was established to educate pharmacists on the concepts and clinical applications of PGx,

PharmGKB at AMIA Summit on Translational Bioinformatics

The American Medical Informatics Association (AMIA) Joint Summits on Translational Science is being held in San Francisco this week. Russ Altman is a keynote speaker at the conference, presenting a review of the past year in Translational Bioinformatics on Wednesday 20th March. Check out Michelle Whirl Carrillo's poster

CPIC publishes guidelines for tricyclic antidepressants and CYPs

Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics. The guideline focuses on amitriptyline and nortriptyline dosing for individuals with CYP2D6 and CYP2C19 haplotypes being treated for depression. Since most studies have examined the effects of CYP2D6 and CYP2C19